Single treatment with the
serotonin (5-hydroxytryptamine)
5-HT1A receptor agonists
8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) and
alnespirone (S-20499) reduces the extracellular
5-HT concentration (5-HText) in the rat midbrain and forebrain. Given the therapeutic potential of selective 5-HT1A agonists in the treatment of
affective disorders, we have examined the changes in 5-HT1A receptors induced by 2-week minipump administration of
alnespirone (0.3 and 3 mg/kg/day) and
8-OH-DPAT (0.1 and 0.3 mg/kg/day). The treatment with
alnespirone did not modify baseline 5-HText but significantly attenuated the ability of 0.3 mg/kg s.c.
alnespirone to reduce 5-HText in the dorsal raphe nucleus (DRN) and frontal cortex. In contrast, the ability of
8-OH-DPAT (0.025 and 0.1 mg/kg s.c.) to reduce 5-HText in both areas was unchanged by
8-OH-DPAT pretreatment. Autoradiographic analysis revealed a significant reduction of [3H]8-
OH-DPAT and [3H]
WAY-100635 [3H-labeled N-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-N-(2-pyridyl)cyclohexa necarboxamide x 3HCl] binding to somatodendritic 5-HT1A receptors (but not to postsynaptic 5-HT1A receptors) of rats pretreated with
alnespirone but not with
8-OH-DPAT. In situ hybridization analysis revealed no change of the density of the
mRNA encoding the 5-HT1A receptors in the DRN after either treatment. These data indicate that continuous treatment for 2 weeks with
alnespirone, but not with
8-OH-DPAT, causes a functional desensitization of somatodendritic 5-HT1A receptors controlling
5-HT release in the DRN and frontal cortex.